Product Contribution. The Parties shall split 50:50 the Product Contribution from Commercialisation of Antibody Products throughout the Territory whether such Product Contribution is a profit or a loss. For the avoidance of doubt, any Commercialisation Expenses incurred prior to Regulatory Approval of an Antibody Product shall be charged to the Product Contribution and be borne by the Parties on a 50:50 basis.
Appears in 3 contracts
Sources: Collaboration and License Agreement (Amgen Inc), Collaboration and License Agreement (Amgen Inc), Collaboration and License Agreement (Amgen Inc)